Evidence map›Paper›PMID 40558490›Full record

ArticleCells2025

Preclinical Assessment in Juvenile Sheep of an Allogeneic Bone Tissue Engineering Product with Wharton's Jelly Mesenchymal Stromal Cells.

Raquel Cabrera-Pérez, Irene Carreras-Sánchez, Ángela Roig-Molina, Alba López-Fernández, Irene Portas-Torres, Laura Batlle-Morera, Roberto Vélez, Joaquim Vives

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Raquel Cabrera-PérezBioprocessing for Advanced Cell Therapies (BACT) Group, Cell Therapy Service, Blood and Tissue Bank (BST), 08005 Barcelona, Catalonia, Spain.ORCID 0000-0002-4858-0142
Irene Carreras-SánchezBioprocessing for Advanced Cell Therapies (BACT) Group, Cell Therapy Service, Blood and Tissue Bank (BST), 08005 Barcelona, Catalonia, Spain.
Ángela Roig-MolinaMusculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Catalonia, Spain.
Alba López-FernándezBioprocessing for Advanced Cell Therapies (BACT) Group, Cell Therapy Service, Blood and Tissue Bank (BST), 08005 Barcelona, Catalonia, Spain.ORCID 0000-0001-6072-0294
Irene Portas-TorresMusculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Catalonia, Spain.ORCID 0000-0003-0661-441X
Laura Batlle-MoreraTissue Engineering Unit, Centre for Genomic Regulation (CRG), Barcelona Biomedical Research Park (PRBB), 08003 Barcelona, Catalonia, Spain.
Roberto VélezMusculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Catalonia, Spain.
Joaquim VivesBioprocessing for Advanced Cell Therapies (BACT) Group, Cell Therapy Service, Blood and Tissue Bank (BST), 08005 Barcelona, Catalonia, Spain.ORCID 0000-0001-9719-5235

Funding

Instituto de Salud Carlos III (ISCIII) PI19/01788
6 · The paper itself

Abstract

Secondary osteonecrosis (ON) is a common complication in paediatric cancer survivors. Combining multipotent mesenchymal stromal cells (MSCs) with core decompression surgery halts disease progression and stimulates bone regeneration. However, the success of advanced therapy medicinal products (ATMPs) requires versatile "off-the-shelf" tissue engineering products (TEPs). This study evaluated the safety and efficacy of TEPs loaded with allogeneic MSCs from Wharton's jelly (WJ-MSCs) in a large-animal model of bone regeneration to support a paediatric investigational plan for ON patients. WJ-MSC-laden fibrin-based hydrogels combined with a synthetic bone substitute (PRO-DENSE

Indexed as

Bone and BonesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationTissue EngineeringWharton JellyAnimalsBone RegenerationBone SubstitutesFemaleMaleOsteogenesisSheepTransplantation, HomologousBone Substitutesadvanced therapy medicinal productbone regenerationfibrinmultipotent mesenchymal stromal cellssynthetic bone substituteWharton’s jelly

Identifiers

PMID40558490
PMCPMC12191425

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.